Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVM14 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Everest Medicines
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
EVM14 + pembrolizumab is an investigational combination therapy being evaluated for the treatment of selected solid tumors. EVM14 is an experimental agent administered intramuscularly, while pembrolizumab is a marketed immune checkpoint inhibitor targeting programmed death 1 (PD-1). The combination aims to enhance anti-tumor immune response, with EVM14 potentially serving as an immunomodulator to prime immune activation and pembrolizumab acting to block immune checkpoint signaling, thus increasing T cell-mediated destruction of cancer cells. The regimen is currently undergoing phase I and IIa clinical investigations to assess safety, tolerability, immunogenicity, and preliminary efficacy in patients with solid tumors[1][4]. Specific details about EVM14's mechanism, molecular nature, and developer remain unpublished as of now.
- Other names
- EVM14 + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on EVM14 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVM14 + pembrolizumab.